IFNG and neoplasm: A subsequent Phase II trial evaluated IFN-γ-primed Dex loaded with MHC class I/II-restricted tumor antigens in patients with unresectable non-small-cell lung cancer (NSCLC) receiving post-induction chemotherapy.